Ray Bergan MD

Genitourinary Oncology

Deputy Director, Fred & Pamela Buffett Cancer Center, Professor Eppley Cancer Institute

986805 Nebraska Medical CenterOmaha, NE 68198
Phone+1 402-559-9536
Fax+1 402-559-4238

Dr. Bergan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bergan's full profile Already have an account?

Summary

Dr. Ray Bergan is a medical oncologist and basic cancer scientist in Omaha, NE and is affiliated with the Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center. He completed fellowships in medical oncology and drug discovery from the National Cancer Institute, Bethesda, MD. He specializes in early phase therapeutics, genitourinary cancer and cancer prevention.

Clinical Expertise

Genitourinary cancer, Preventive medicine, Clinical research, Laboratory research, Medical oncology

Education & Training

University of Nebraska Medical Centercurrently matriculated, Academic Leaders Course, 2021 - 2022
Harvard T.H. Chan School of Public HealthCertificate of Completion, Leadership Development Course, 2015 - 2015
National Cancer InstituteLab research, cell biology, 1993 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1987 - 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 1988 - 2027
NE State Medical License 2020 - 2026
OR State Medical License 2015 - 2023
IL State Medical License 1998 - 2017
MD State Medical License 1991 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017

Clinical Trials

Iloprost in Preventing Lung Cancer in Former Smokers Start of enrollment: 2015 Nov 05
COMPLETED
PHASE1
The Registry of Oncology Outcomes Associated with Testing and Treatment Start of enrollment: 2021 May 05
COMPLETED
Oltipraz in the Prevention of Lung Cancer in People Who Smoke
COMPLETED
PHASE1

Publications & Presentations

PubMed

Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (-rate) based machine learning model.
Esther C Ugwueke, Mohamed Azzam, Mengxi Zhou, Benjamin A Teply, Raymond C Bergan
Medrxiv. 2026-03-03
HSP90α and KLK6 Coregulate Stress-Induced Prostate Cancer Cell Motility.
Katelyn L O'Neill, Johnny W Zigmond, Raymond Bergan
Cells. 2026-01-16
HSP90α and KLK6 Co-Regulate Stress-Induced Prostate Cancer Cell Motility.
Katelyn L O'Neill, Johnny W Zigmond, Raymond Bergan
Biorxiv. 2025-12-29

Authored Content

Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistFebruary 2022
Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistFebruary 2022

Press Mentions

Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistJuly 10th, 2022
Why Your Doctor Should Also Be a ScientistJuly 10th, 2022

Grant Support

Fred & Pamela Buffett Cancer CenterNational Cancer Institute2021–2026
Inhibiting Bone Destruction by Prostate Cancer with Dual-Acting Bone-Defending AgentsDOD, Prostate Cancer Research Program, Idea Development Award2020–2023
Knight Cancer InstituteNational Cancer Institute2017–2022
The Quantitation of Protein Interactions in Cancer CellsNIH2016–2021
Serial Measurement of Molecular Architecture and Response to TherapyProspect Creek Foundation2016–2019